{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:22:26Z","timestamp":1782098546442,"version":"3.54.5"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,3,29]],"date-time":"2016-03-29T00:00:00Z","timestamp":1459209600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s40264-016-0416-y","type":"journal-article","created":{"date-parts":[[2016,3,29]],"date-time":"2016-03-29T14:37:53Z","timestamp":1459262273000},"page":"627-645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence"],"prefix":"10.1007","volume":"39","author":[{"given":"Julia M. A.","family":"Sinclair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia E.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia J.","family":"Shiles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,29]]},"reference":[{"key":"416_CR1","volume-title":"Global status report on alcohol and health-2014","author":"WHO","year":"2014","unstructured":"WHO. Global status report on alcohol and health-2014. Geneva: World Health Organization; 2014."},{"issue":"7","key":"416_CR2","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/archpsyc.64.7.830","volume":"64","author":"DS Hasin","year":"2007","unstructured":"Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64(7):830\u201342.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"416_CR3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.euroneuro.2012.08.001","volume":"23","author":"J Rehm","year":"2013","unstructured":"Rehm J, Shield K, Gmel G, Rehm M, Frick U. Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol. 2013;23(2):89\u201397.","journal-title":"Eur Neuropsychopharmacol"},{"key":"416_CR4","unstructured":"National Collaborating Centre for Mental Health (UK). Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. The British Psychological Society and The Royal College of Psychiatrists Publications; 2011."},{"key":"416_CR5","first-page":"CD008537","volume":"6","author":"L Amato","year":"2011","unstructured":"Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev. 2011;6:CD008537.","journal-title":"Cochrane Database Syst Rev"},{"key":"416_CR6","first-page":"CD004332","volume":"9","author":"S R\u00f6sner","year":"2010","unstructured":"R\u00f6sner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;9:CD004332.","journal-title":"Cochrane Database Syst Rev"},{"key":"416_CR7","first-page":"CD001867","volume":"12","author":"S R\u00f6sner","year":"2010","unstructured":"R\u00f6sner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;12:CD001867.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"416_CR8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269881112444324","volume":"26","author":"AR Lingford-Hughes","year":"2012","unstructured":"Lingford-Hughes AR, Welch S, Peters L, Nutt DJ. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol. 2012;26(7):899\u2013952.","journal-title":"J Psychopharmacol."},{"issue":"9237","key":"416_CR9","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255\u20139.","journal-title":"Lancet"},{"issue":"4","key":"416_CR10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139.","journal-title":"Ann Intern Med"},{"issue":"5","key":"416_CR11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surgery. 2010;8(5):336\u201341.","journal-title":"Int J Surgery."},{"issue":"5","key":"416_CR12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/hup.2329","volume":"28","author":"B Talat","year":"2013","unstructured":"Talat B, Mayers A, Baldwin DS. Quality of case reports of adverse drug reactions with psychotropic drugs: a 25-year review. Hum Psychopharmacol. 2013;28(5):413\u201320.","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"416_CR13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcp.12070","volume":"77","author":"NJ Kalk","year":"2014","unstructured":"Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2014;77(2):315\u201323.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"416_CR14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archgenpsychiatry.2010.125","volume":"67","author":"JC Umhau","year":"2010","unstructured":"Umhau JC, Momenan R, Schwandt ML, Singley E, Lifshitz M, Doty L, et al. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry. 2010;67(10):1069\u201377.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"416_CR15","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/add.12875","volume":"110","author":"K Donoghue","year":"2015","unstructured":"Donoghue K, Elzerbi C, Saunders R, Whittington C, Pilling S, Drummond C. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction. 2015;110(6):920\u201330.","journal-title":"Addiction."},{"key":"416_CR16","unstructured":"Electronic Medicines Compendium (eMC). Campral EC 2015. http:\/\/www.medicines.org.uk\/emc\/medicine\/1042\/SPC\/Campral+EC\/ . Accessed 3 Sep 2015."},{"issue":"3","key":"416_CR17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1530-0277.1998.tb04295.x","volume":"22","author":"J Besson","year":"1998","unstructured":"Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res. 1998;22(3):573\u20139.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"416_CR18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/ADM.0b013e31816319fd","volume":"2","author":"RN Rosenthal","year":"2008","unstructured":"Rosenthal RN, Gage A, Perhach JL, Goodman AM. Acamprosate: safety and tolerability in the treatment of alcohol dependence. J Addict Med. 2008;2(1):40\u201350.","journal-title":"J Addict Med."},{"issue":"6","key":"416_CR19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/oxfordjournals.alcalc.a045057","volume":"25","author":"J Lhuintre","year":"1990","unstructured":"Lhuintre J, Moore N, Tran G, Steru L, Langrenon S, Daoust S, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol. 1990;25(6):613\u201322.","journal-title":"Alcohol Alcohol"},{"issue":"11","key":"416_CR20","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/j.1360-0443.1997.tb02873.x","volume":"92","author":"F Poldrugo","year":"1997","unstructured":"Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction. 1997;92(11):1537\u201346.","journal-title":"Addiction."},{"issue":"3","key":"416_CR21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0091-3057(89)90005-1","volume":"32","author":"K Grant","year":"1989","unstructured":"Grant K, Woolverton WL. Reinforcing and discriminative stimulus effects of ca-acetyl homotaurine in animals. Pharmacol Biochem Behav. 1989;32(3):607\u201311.","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"416_CR22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/alcalc\/35.2.176","volume":"35","author":"J Chick","year":"2000","unstructured":"Chick J, Howlett H, Morgan M, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000;35(2):176\u201387.","journal-title":"Alcohol Alcohol"},{"issue":"6","key":"416_CR23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euroneuro.2003.08.009","volume":"13","author":"BJ Mason","year":"2003","unstructured":"Mason BJ. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. Eur Neuropsychopharmacol. 2003;13(6):469\u201375.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8436","key":"416_CR24","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(85)91615-0","volume":"325","author":"J-P Lhuintre","year":"1985","unstructured":"Lhuintre J-P, Moore N, Saligaut C, Boismare F, Daoust M, Chretien P, et al. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet. 1985;325(8436):1014\u20136.","journal-title":"Lancet"},{"issue":"2","key":"416_CR25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4088\/JCP.13m08940","volume":"76","author":"S Higuchi","year":"2015","unstructured":"Higuchi S. Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (sunrise study). J Clin Psychiatry. 2015;76(2):181\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"416_CR26","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/adb.12012","volume":"18","author":"K Mann","year":"2013","unstructured":"Mann K, Lemenager T, Hoffmann S, Reinhard I, Hermann D, Batra A, et al. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013;18(6):937\u201346.","journal-title":"Addict Biol"},{"issue":"2","key":"416_CR27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/alcalc\/35.2.202","volume":"35","author":"E Tempesta","year":"2000","unstructured":"Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol. 2000;35(2):202\u20139.","journal-title":"Alcohol Alcohol"},{"issue":"5","key":"416_CR28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/alcalc\/36.5.413","volume":"36","author":"A Gual","year":"2001","unstructured":"Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol. 2001;36(5):413\u20138.","journal-title":"Alcohol Alcohol"},{"issue":"6","key":"416_CR29","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.addbeh.2009.03.014","volume":"34","author":"KM Kampman","year":"2009","unstructured":"Kampman KM, Pettinati HM, Lynch KG, Xie H, Dackis C, Oslin DW, et al. Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behav. 2009;34(6):581\u20136.","journal-title":"Addict Behav"},{"issue":"2","key":"416_CR30","first-page":"239","volume":"30","author":"FM Paille","year":"1995","unstructured":"Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30(2):239\u201347.","journal-title":"Alcohol Alcohol"},{"issue":"1","key":"416_CR31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1192\/bjp.171.1.73","volume":"171","author":"I Pelc","year":"1997","unstructured":"Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171(1):73\u20137.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"416_CR32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","volume":"60","author":"F Kiefer","year":"2003","unstructured":"Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60(1):92\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"17","key":"416_CR33","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","volume":"295","author":"RF Anton","year":"2006","unstructured":"Anton RF, O\u2019Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003\u201317.","journal-title":"JAMA"},{"issue":"7","key":"416_CR34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/NMD.0b013e3182214297","volume":"199","author":"E Ralevski","year":"2011","unstructured":"Ralevski E, O\u2019Brien E, Jane JS, Dean E, Dwan R, Petrakis I. Effects of acamprosate on cognition in a treatment study of patients with schizophrenia spectrum disorders and comorbid alcohol dependence. J Nerv Ment Dis. 2011;199(7):499\u2013505.","journal-title":"J Nerv Ment Dis."},{"issue":"1","key":"416_CR35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1399-5618.2011.00973.x","volume":"14","author":"BK Tolliver","year":"2012","unstructured":"Tolliver BK, DeSantis SM, Brown DG, Prisciandaro JJ, Brady KT. A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2012;14(1):54\u201363.","journal-title":"Bipolar Disord"},{"issue":"1","key":"416_CR36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/alcalc\/agq077","volume":"46","author":"M Lejoyeux","year":"2011","unstructured":"Lejoyeux M, Lehert P. Alcohol-use disorders and depression: results from individual patient data meta-analysis of the acamprosate-controlled studies. Alcohol Alcohol. 2011;46(1):61\u20137.","journal-title":"Alcohol Alcohol"},{"issue":"12","key":"416_CR37","first-page":"927","volume":"26","author":"W Sun","year":"2012","unstructured":"Sun W, Xu X-F, Huang J-Z, Tan Q-R, Deng H-H, Li K-Q, et al. A 12-week randomized, double-blind, placebo-controlled multicenter clinical trial of acamprosate for the treatment of alcohol dependence. Chin Mental Health J. 2012;26(12):927\u201332.","journal-title":"Chin Mental Health J."},{"issue":"3","key":"416_CR38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1530-0277.2011.01616.x","volume":"36","author":"BJ Mason","year":"2012","unstructured":"Mason BJ, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res. 2012;36(3):497\u2013508.","journal-title":"Alcohol Clin Exp Res"},{"key":"416_CR39","unstructured":"McEvoy GK, editor. AHFS drug information 2000. Bethesda: American Society of Health-System Pharmacists; 2000."},{"issue":"5","key":"416_CR40","first-page":"906","volume":"21","author":"AC King","year":"1997","unstructured":"King AC, Volpicelli JR, Gunduz M, O\u2019Brien CP, Kreek MJ. Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res. 1997;21(5):906\u20139.","journal-title":"Alcohol Clin Exp Res"},{"key":"416_CR41","unstructured":"Electronic Medicines Compendium (eMC). Adepend 50\u00a0mg filmcoated tablets 2014. http:\/\/www.medicines.org.uk\/emc\/medicine\/29642 . Accessed 3 Sep 2015."},{"issue":"6","key":"416_CR42","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/00004714-200112000-00024","volume":"21","author":"SW Kim","year":"2001","unstructured":"Kim SW, Grant JE, Adson DE, Remmel RP. A preliminary report on possible naltrexone and nonsteroidal analgesic interactions. J Clin Psychopharmacol. 2001;21(6):632\u20134.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"416_CR43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0006-3223(87)90127-2","volume":"22","author":"JE Mitchell","year":"1987","unstructured":"Mitchell JE, Morley JE, Levine AS, Hatsukami D, Gannon M, Pfohl D. High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry. 1987;22(1):35\u201342.","journal-title":"Biol Psychiatry"},{"issue":"9","key":"416_CR44","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/j.1552-4604.1994.tb04002.x","volume":"34","author":"DS Sax","year":"1994","unstructured":"Sax DS, Kornetsky C, Kim A. Lack of hepatotoxicity with naltrexone treatment. J Clin Pharmacol. 1994;34(9):898\u2013901.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"416_CR45","first-page":"143","volume":"19","author":"M Marrazzi","year":"1995","unstructured":"Marrazzi M, Markham K, Kinzie J, Luby E. Binge eating disorder: response to naltrexone. Int J Obes Relat Metab Disord. 1995;19(2):143\u20135.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"2","key":"416_CR46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00002826-200603000-00004","volume":"29","author":"SW Kim","year":"2006","unstructured":"Kim SW, Grant JE, Yoon G, Williams KA, Remmel RP. Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients. Clin Neuropharmacol. 2006;29(2):77\u20139.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"416_CR47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/alcalc\/35.1.91","volume":"35","author":"J Budzy\u0144ski","year":"2000","unstructured":"Budzy\u0144ski J, Rybakowski J, \u015awi\u0105tkowski M, Torli\u0144ski L, K\u0142opocka M, Kosmowski W, et al. Naltrexone exerts a favourable effect on plasma lipids in abstinent patients with alcohol dependence. Alcohol Alcohol. 2000;35(1):91\u20137.","journal-title":"Alcohol Alcohol"},{"issue":"5","key":"416_CR48","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/14659891.2013.813084","volume":"19","author":"A Sousa De","year":"2014","unstructured":"De Sousa A. A comparative study using disulfiram and naltrexone in alcohol-dependent adolescents. J Subst Use. 2014;19(5):341\u20135.","journal-title":"J Subst Use."},{"issue":"4","key":"416_CR49","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00019442-199700540-00007","volume":"5","author":"D Oslin","year":"1997","unstructured":"Oslin D, Liberto JG, O\u2019Brien J, Krois S, Norbeck J. Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry. 1997;5(4):324\u201332.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"6","key":"416_CR50","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1176\/appi.ajp.2009.08060852","volume":"167","author":"HM Pettinati","year":"2010","unstructured":"Pettinati HM, Oslin DW, Kampman KM, Dundon WD, Xie H, Gallis TL, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010;167(6):668\u201375.","journal-title":"Am J Psychiatry"},{"issue":"7","key":"416_CR51","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1530-0277.2008.00698.x","volume":"32","author":"DW Oslin","year":"2008","unstructured":"Oslin DW, Lynch KG, Pettinati HM, Kampman KM, Gariti P, Gelfand L, et al. A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res. 2008;32(7):1299\u2013308.","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"416_CR52","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/105504901750532148","volume":"10","author":"JR Monterosso","year":"2001","unstructured":"Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O\u2019Brien CP, et al. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict. 2001;10(3):258\u201368.","journal-title":"Am J Addict."},{"issue":"5","key":"416_CR53","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.addbeh.2007.11.011","volume":"33","author":"HM Pettinati","year":"2008","unstructured":"Pettinati HM, Kampman KM, Lynch KG, Xie H, Dackis C, Rabinowitz AR, et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav. 2008;33(5):651\u201367.","journal-title":"Addict Behav"},{"issue":"5","key":"416_CR54","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3109\/10550490903077929","volume":"18","author":"JM Schmitz","year":"2009","unstructured":"Schmitz JM, Lindsay JA, Green CE, Herin DV, Stotts AL, Gerard Moeller F. High-dose naltrexone therapy for cocaine-alcohol dependence. Am J Addict. 2009;18(5):356\u201362.","journal-title":"Am J Addict."},{"issue":"4","key":"416_CR55","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jsat.2007.05.011","volume":"34","author":"HM Pettinati","year":"2008","unstructured":"Pettinati HM, Kampman KM, Lynch KG, Suh JJ, Dackis CA, Oslin DW, et al. Gender differences with high dose naltrexone in cocaine and alcohol dependent patients. J Subst Abuse Treat. 2008;34(4):378\u201390.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"416_CR56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/hup.1183","volume":"26","author":"G Yoon","year":"2011","unstructured":"Yoon G, Kim SW, Thuras P, Westermeyer J. Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: an open-label study. Hum Psychopharmacol. 2011;26(2):125\u201332.","journal-title":"Hum Psychopharmacol"},{"issue":"11","key":"416_CR57","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0006-3223(01)01079-4","volume":"49","author":"SW Kim","year":"2001","unstructured":"Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49(11):914\u201321.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"416_CR58","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/alcalc\/36.5.419","volume":"36","author":"G Rubio","year":"2001","unstructured":"Rubio G, Jimenez-Arriero M, Ponce G, Palomo T. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol. 2001;36(5):419\u201325.","journal-title":"Alcohol Alcohol"},{"issue":"10","key":"416_CR59","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.biopsych.2005.02.016","volume":"57","author":"IL Petrakis","year":"2005","unstructured":"Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry. 2005;57(10):1128\u201337.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"416_CR60","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1530-0277.2000.tb02048.x","volume":"24","author":"BA Johnson","year":"2000","unstructured":"Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res. 2000;24(5):737\u201342.","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"416_CR61","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archpsyc.65.4.466","volume":"65","author":"H Myrick","year":"2008","unstructured":"Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K. Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry. 2008;65(4):466\u201375.","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"416_CR62","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.euroneuro.2007.04.008","volume":"17","author":"F Caputo","year":"2007","unstructured":"Caputo F, Addolorato G, Stoppo M, Francini S, Vignoli T, Lorenzini F, et al. Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomized comparative study. Eur Neuropsychopharmacol. 2007;17(12):781\u20139.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"416_CR63","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.phrs.2008.03.001","volume":"57","author":"L Stella","year":"2008","unstructured":"Stella L, Addolorato G, Rinaldi B, Capuano A, Berrino L, Rossi F, et al. An open randomized study of the treatment of escitalopram alone and combined with \u03b3-hydroxybutyric acid and naltrexone in alcoholic patients. Pharmacol Res. 2008;57(4):312\u20137.","journal-title":"Pharmacol Res"},{"issue":"7","key":"416_CR64","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1530-0277.2008.00682.x","volume":"32","author":"SS O\u2019Malley","year":"2008","unstructured":"O\u2019Malley SS, Robin RW, Levenson AL, GreyWolf I, Chance LE, Hodgkinson CA, et al. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res. 2008;32(7):1271\u201383.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"416_CR65","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.drugalcdep.2008.06.006","volume":"99","author":"CK Farren","year":"2009","unstructured":"Farren CK, Scimeca M, Wu R, Malley SO. A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. Drug Alcohol Depend. 2009;99(1):317\u201321.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"416_CR66","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.addbeh.2010.11.006","volume":"36","author":"J Guardia","year":"2011","unstructured":"Guardia J, Roncero C, Galan J, Gonzalvo B, Burguete T, Casas M. A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients. Addict Behav. 2011;36(3):265\u20139.","journal-title":"Addict Behav"},{"issue":"4","key":"416_CR67","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/10550490490480982","volume":"13","author":"JM Schmitz","year":"2004","unstructured":"Schmitz JM, Stotts AL, Sayre SL, DeLaune KA, Grabowski J. Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. Am J Addict. 2004;13(4):333\u201341.","journal-title":"Am J Addict."},{"issue":"1\u20132","key":"416_CR68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s002130050688","volume":"139","author":"D Hersh","year":"1998","unstructured":"Hersh D, Van Kirk JR, Kranzler HR. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology. 1998;139(1\u20132):44\u201352.","journal-title":"Psychopharmacology"},{"issue":"6","key":"416_CR69","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/10550490802409074","volume":"17","author":"JJ Suh","year":"2008","unstructured":"Suh JJ, Pettinati HM, Kampman KM, O\u2019Brien CP. Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. Am J Addict. 2008;17(6):463\u20138.","journal-title":"Am J Addict."},{"issue":"2","key":"416_CR70","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jsat.2008.11.007","volume":"37","author":"KR Conner","year":"2009","unstructured":"Conner KR, Pinquart M, Gamble SA. Meta-analysis of depression and substance use among individuals with alcohol use disorders. J Subst Abuse Treat. 2009;37(2):127\u201337.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"416_CR71","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1192\/bjp.166.2.199","volume":"166","author":"KM Davidson","year":"1995","unstructured":"Davidson KM. Diagnosis of depression in alcohol dependence: changes in prevalence with drinking status. Br J Psychiatry. 1995;166(2):199\u2013204.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"416_CR72","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00019442-200506000-00008","volume":"13","author":"DW Oslin","year":"2005","unstructured":"Oslin DW. Treatment of late-life depression complicated by alcohol dependence. Am J Geriatr Psychiatry. 2005;13(6):491\u2013500.","journal-title":"Am J Geriatr Psychiatry."},{"issue":"2","key":"416_CR73","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/JCP.0000000000000287","volume":"35","author":"SJ Adamson","year":"2015","unstructured":"Adamson SJ, Sellman JD, Foulds JA, Frampton CMA, Deering D, Dunn A, et al. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. J Clin Psychopharmacol. 2015;35(2):143\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"416_CR74","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/jcp.0b13e3180337fcb","volume":"27","author":"I Petrakis","year":"2007","unstructured":"Petrakis I, Ralevski E, Nich C, Levinson C, Carroll K, Poling J, et al. Naltrexone and disulfiram in patients with alcohol dependence and current depression. J Clin Psychopharmacol. 2007;27(2):160\u20135.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"416_CR75","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/j.1530-0277.2009.01024.x","volume":"33","author":"ES Brown","year":"2009","unstructured":"Brown ES, Carmody TJ, Schmitz JM, Caetano R, Adinoff B, Swann AC, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res. 2009;33(11):1863\u20139.","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"416_CR76","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/schbul\/sbl010","volume":"32","author":"IL Petrakis","year":"2006","unstructured":"Petrakis IL, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull. 2006;32(4):644\u201354.","journal-title":"Schizophr Bull"},{"issue":"3","key":"416_CR77","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00213-003-1658-9","volume":"172","author":"IL Petrakis","year":"2004","unstructured":"Petrakis IL, O\u2019Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology. 2004;172(3):291\u20137.","journal-title":"Psychopharmacology"},{"issue":"7","key":"416_CR78","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.biopsych.2006.03.074","volume":"60","author":"IL Petrakis","year":"2006","unstructured":"Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Ralevski E, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol Psychiatry. 2006;60(7):777\u201383.","journal-title":"Biol Psychiatry"},{"issue":"4","key":"416_CR79","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/npp.2011.283","volume":"37","author":"IL Petrakis","year":"2012","unstructured":"Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, et al. Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacology. 2012;37(4):996\u20131004.","journal-title":"Neuropsychopharmacology."},{"issue":"11","key":"416_CR80","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1097\/01.ALC.0000145688.30448.2C","volume":"28","author":"TK Killeen","year":"2004","unstructured":"Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C, et al. Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res. 2004;28(11):1710\u20137.","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"416_CR81","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0893-133X(99)00135-9","volume":"22","author":"HR Kranzler","year":"2000","unstructured":"Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence: a placebo-controlled trial. Neuropsychopharmacology. 2000;22(5):493\u2013503.","journal-title":"Neuropsychopharmacology."},{"issue":"11","key":"416_CR82","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1046\/j.1360-0443.2001.961115654.x","volume":"96","author":"PLP Morris","year":"2001","unstructured":"Morris PLP, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96(11):1565\u201373.","journal-title":"Addiction."},{"issue":"4","key":"416_CR83","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1530-0277.2007.00347.x","volume":"31","author":"SS O\u2019Malley","year":"2007","unstructured":"O\u2019Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, et al. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res. 2007;31(4):625\u201334.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"416_CR84","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00004714-200002000-00012","volume":"20","author":"SS O\u2019Malley","year":"2000","unstructured":"O\u2019Malley SS, Krishnan-Sarin S, Farren C, O\u2019Connor PG. Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects. J Clin Psychopharmacol. 2000;20(1):69\u201376.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"416_CR85","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1530-0277.2008.00633.x","volume":"32","author":"A Baros","year":"2008","unstructured":"Baros A, Latham P, Anton R. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res. 2008;32(5):771\u20136.","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"416_CR86","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01.jcp.0000172071.81258.04","volume":"25","author":"RF Anton","year":"2005","unstructured":"Anton RF, Moak DH, Latham P, Waid LR, Myrick H, Voronin K, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005;25(4):349\u201357.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"416_CR87","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1176\/ajp.156.11.1758","volume":"156","author":"RF Anton","year":"1999","unstructured":"Anton RF, Moak DH, Waid RL, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156(11):1758\u201364.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"416_CR88","first-page":"85","volume":"5","author":"J Ahmadi","year":"2002","unstructured":"Ahmadi J, Ahmadi N. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence. German J Psychiatry. 2002;5(4):85\u20139.","journal-title":"German J Psychiatry."},{"issue":"3","key":"416_CR89","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/13556210500223504","volume":"10","author":"MC Huang","year":"2005","unstructured":"Huang MC, Chen CH, Yu JM, Chen CC. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan. Addict Biol. 2005;10(3):289\u201392.","journal-title":"Addict Biol"},{"issue":"2","key":"416_CR90","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/09595230120058579","volume":"20","author":"A Lee","year":"2001","unstructured":"Lee A, Tan S, Lim D, Winslow RM, Wong KE, Allen J, et al. Naltrexone in the treatment of male alcoholics\u2014an effectiveness study in Singapore. Drug Alcohol Rev. 2001;20(2):193\u20139.","journal-title":"Drug Alcohol Rev."},{"issue":"6","key":"416_CR91","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/alcalc\/35.6.587","volume":"35","author":"J Chick","year":"2000","unstructured":"Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35(6):587\u201393.","journal-title":"Alcohol Alcohol"},{"issue":"8","key":"416_CR92","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.1997.01830200071010","volume":"54","author":"JR Volpicelli","year":"1997","unstructured":"Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O\u2019Brien CP. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54(8):737\u201342.","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"416_CR93","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/01.ALC.0000139823.30096.52","volume":"28","author":"BA Johnson","year":"2004","unstructured":"Johnson BA, Ait-Daoud N, Aubin H-J, van den Brink W, Guzzetta R, Loewy J, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex\u00ae) in patients with alcohol dependence. Alcohol Clin Exp Res. 2004;28(9):1356\u201361.","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"416_CR94","first-page":"1074","volume":"22","author":"HR Kranzler","year":"1998","unstructured":"Kranzler HR, Modesto-Lowe V, Nuwayser ES. Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res. 1998;22(5):1074\u20139.","journal-title":"Alcohol Clin Exp Res"},{"issue":"7","key":"416_CR95","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.ALC.0000130804.08397.29","volume":"28","author":"HR Kranzler","year":"2004","unstructured":"Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28(7):1051\u20139.","journal-title":"Alcohol Clin Exp Res"},{"issue":"13","key":"416_CR96","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","volume":"293","author":"JC Garbutt","year":"2005","unstructured":"Garbutt JC, Kranzler HR, O\u2019Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617\u201325.","journal-title":"JAMA"},{"issue":"4","key":"416_CR97","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.1984.213","volume":"36","author":"MD Faiman","year":"1984","unstructured":"Faiman MD, Jensen JC, Lacoursiere RB. Elimination kinetics of disulfiram in alcoholics after single and repeated doses. Clin Pharmacol Ther. 1984;36(4):520\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"416_CR98","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14740338.7.4.459","volume":"7","author":"R Malcolm","year":"2008","unstructured":"Malcolm R, Olive MF, Lechner W. The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: guidance for clinical practice. Expert Opin Drug Saf. 2008;7(4):459\u201372.","journal-title":"Expert Opin Drug Saf."},{"issue":"4","key":"416_CR99","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0447.1984.tb02496.x","volume":"69","author":"J Christensen","year":"1984","unstructured":"Christensen J, R\u00f8nsted P, Vaag U. Side effects after disulfiram. Acta Psychiatr Scand. 1984;69(4):265\u201373.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"416_CR100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1365-2125.2002.01522.x","volume":"53","author":"RF Frye","year":"2002","unstructured":"Frye RF, Branch RA. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. Br J Clin Pharmacol. 2002;53(2):155\u201362.","journal-title":"Br J Clin Pharmacol"},{"key":"416_CR101","unstructured":"Electronic Medicines Compendium (eMC). Disulfiram Tablets 200\u00a0mg 2012. http:\/\/www.medicines.org.uk\/emc\/medicine\/519 . Accessed 3 Sep 2015."},{"issue":"2","key":"416_CR102","doi-asserted-by":"crossref","first-page":"446","DOI":"10.15288\/qjsa.1970.31.446","volume":"31","author":"E Rothstein","year":"1970","unstructured":"Rothstein E, Clancy DD. Combined use of disulfiram and metronidazole in treatment of alcoholism. Q J Stud Alcohol. 1970;31(2):446\u20137.","journal-title":"Q J Stud Alcohol"},{"issue":"1","key":"416_CR103","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5455\/njppp.2013.3.35000","volume":"3","author":"G Kumaraswamy","year":"2013","unstructured":"Kumaraswamy G, Pundarikaksha H, Ramaiah V, Anjanappa J. A study of cardiovascular complications of disulfiram-ethanol reaction. Natl J Physiol Pharmacy Pharmacol. 2013;3(1):35\u201342.","journal-title":"Natl J Physiol Pharmacy Pharmacol."},{"issue":"1","key":"416_CR104","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1192\/bjp.161.1.84","volume":"161","author":"J Chick","year":"1992","unstructured":"Chick J, Gough K, Falkowski W, Kershaw P, Hore B, Mehta B, et al. Disulfiram treatment of alcoholism. Br J Psychiatry. 1992;161(1):84\u20139.","journal-title":"Br J Psychiatry"},{"issue":"11","key":"416_CR105","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","volume":"256","author":"RK Fuller","year":"1986","unstructured":"Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA. 1986;256(11):1449\u201355.","journal-title":"JAMA"},{"issue":"3","key":"416_CR106","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1530-0277.1987.tb01312.x","volume":"11","author":"FL Iber","year":"1987","unstructured":"Iber FL, Lee K, Lacoursiere R, Fuller R. Liver toxicity encountered in the Veterans Administration trial of disulfiram in alcoholics. Alcohol Clin Exp Res. 1987;11(3):301\u20134.","journal-title":"Alcohol Clin Exp Res"},{"issue":"6","key":"416_CR107","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3109\/08039481003686180","volume":"64","author":"J Ulrichsen","year":"2010","unstructured":"Ulrichsen J, Nielsen MK, Ulrichsen M. Disulfiram in severe alcoholism\u2014an open controlled study. Nordic J Psychiatry. 2010;64(6):356\u201362.","journal-title":"Nordic J Psychiatry."},{"issue":"5","key":"416_CR108","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/WNF.0b013e3182285e2d","volume":"34","author":"J Mutschler","year":"2011","unstructured":"Mutschler J, Dirican G, Gutzeit A, Grosshans M. Safety and efficacy of long-term disulfiram aftercare. Clin Neuropharmacol. 2011;34(5):195\u20138.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"416_CR109","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/0019-5545.75557","volume":"53","author":"PL Palatty","year":"2011","unstructured":"Palatty PL, Saldanha E. Status of disulfiram in present day alcoholic deaddiction therapy. Indian J Psychiatry. 2011;53(1):25.","journal-title":"Indian J Psychiatry."},{"issue":"5","key":"416_CR110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00002018-199920050-00003","volume":"20","author":"J Chick","year":"1999","unstructured":"Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf. 1999;20(5):427\u201335.","journal-title":"Drug Saf"},{"issue":"3","key":"416_CR111","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/0959523031000154436","volume":"22","author":"H Niederhofer","year":"2003","unstructured":"Niederhofer H, Staffen W. Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents. Drug Alcohol Rev. 2003;22(3):295\u20137.","journal-title":"Drug Alcohol Rev."},{"issue":"3","key":"416_CR112","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15288\/jsa.1984.45.209","volume":"45","author":"PF Goyer","year":"1984","unstructured":"Goyer PF, Brown GL, Minichiello MD, Major LF. Mood-altering effects of disulfiram in alcoholics. J Stud Alcohol. 1984;45(3):209\u201313.","journal-title":"J Stud Alcohol"},{"issue":"8","key":"416_CR113","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archpsyc.1983.01790070041005","volume":"40","author":"W Ling","year":"1983","unstructured":"Ling W, Weiss DG, Charuvastra VC, O\u2019Brien CP, Blakis M, Wang R, et al. Use of disulfiram for alcoholics in methadone maintenance programs: a Veterans Administration cooperative study. Arch Gen Psychiatry. 1983;40(8):851\u20134.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"416_CR114","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/WNF.0000000000000050","volume":"37","author":"M Specka","year":"2014","unstructured":"Specka M, Heilmann M, Lieb B, Scherbaum N. Use of disulfiram for alcohol relapse prevention in patients in opioid maintenance treatment. Clin Neuropharmacol. 2014;37(6):161\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"416_CR115","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1360-0443.1998.9357137.x","volume":"93","author":"KM Carroll","year":"1998","unstructured":"Carroll KM, Nich C, Ball SA, McCance E, Rounsavile BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction. 1998;93(5):713\u201327.","journal-title":"Addiction."},{"issue":"1","key":"416_CR116","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0773.1993.tb01331.x","volume":"72","author":"NL Benowitz","year":"1993","unstructured":"Benowitz NL. Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol. 1993;72(1):3\u201312.","journal-title":"Pharmacol Toxicol"},{"issue":"1","key":"416_CR117","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1530-0277.1992.tb00648.x","volume":"16","author":"EW Larson","year":"1992","unstructured":"Larson EW, Olincy A, Rummans TA, Morse RM. Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review. Alcohol Clin Exp Res. 1992;16(1):125\u201330.","journal-title":"Alcohol Clin Exp Res"},{"issue":"8","key":"416_CR118","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopsych.2013.03.002","volume":"73","author":"RM Swift","year":"2013","unstructured":"Swift RM. Naltrexone and nalmefene: any meaningful difference? Biol Psychiatry. 2013;73(8):700\u20131.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"416_CR119","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/clpt.1991.32","volume":"49","author":"PJ Fudala","year":"1991","unstructured":"Fudala PJ, Heishman SJ, Henningfield JE, Johnson RE. Human pharmacology and abuse potential of nalmefene. Clin Pharmacol Ther. 1991;49(3):300\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"416_CR120","unstructured":"European Medicines Agency. Selincro 2015. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002583\/human_med_001620.jsp&mid=WC0b01ac058001d124 . Accessed 3 Sep 2015."},{"issue":"8","key":"416_CR121","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","volume":"56","author":"BJ Mason","year":"1999","unstructured":"Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56(8):719\u201324.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"416_CR122","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0009-9236(97)90178-8","volume":"61","author":"RF Frye","year":"1997","unstructured":"Frye RF, Matzke GR, Schade R, Dixon R, Rabinovitz M. Effects of liver disease on the disposition of the opioid antagonist nalmefene. Clin Pharmacol Ther. 1997;61(1):15\u201323.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"416_CR123","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.jcp.0000130555.63254.73","volume":"24","author":"RF Anton","year":"2004","unstructured":"Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24(4):421\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"416_CR124","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/sj.npp.1300101","volume":"28","author":"DJ Drobes","year":"2003","unstructured":"Drobes DJ, Anton RF, Thomas SE, Voronin K. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology. 2003;28(4):755\u201364.","journal-title":"Neuropsychopharmacology."},{"issue":"11","key":"416_CR125","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","volume":"23","author":"A Gual","year":"2013","unstructured":"Gual A, He Y, Torup L, van den Brink W, Mann K, Group ES. A randomized, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013;23(11):1432\u201342.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"416_CR126","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","volume":"73","author":"K Mann","year":"2013","unstructured":"Mann K, Bladstr\u00f6m A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73(8):706\u201313.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"416_CR127","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0269881114527362","volume":"28","author":"W Brink van den","year":"2014","unstructured":"van den Brink W, S\u00f8rensen P, Torup L, Mann K, Gual A. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study. J Psychopharmacol. 2014;28(8):733\u201344.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"416_CR128","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/14740338.2015.1011619","volume":"14","author":"W Brink van den","year":"2015","unstructured":"van den Brink W, Strang J, Gual A, S\u00f8rensen P, Jensen TJ, Mann K. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Exp Opin Drug Saf. 2015;14(4):495\u2013504.","journal-title":"Exp Opin Drug Saf."},{"key":"416_CR129","unstructured":"Electronic Medicines Compendium (eMC). Baclofen Tablets BP 10\u00a0mg 2012. http:\/\/www.medicines.org.uk\/emc\/medicine\/23850 . Accessed 3 Sep 2015."},{"issue":"5","key":"416_CR130","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","volume":"37","author":"G Addolorato","year":"2002","unstructured":"Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37(5):504\u20138.","journal-title":"Alcohol Alcohol"},{"issue":"9603","key":"416_CR131","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","volume":"370","author":"G Addolorato","year":"2007","unstructured":"Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915\u201322.","journal-title":"Lancet"},{"issue":"8","key":"416_CR132","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.euroneuro.2015.04.002","volume":"25","author":"CA M\u00fcller","year":"2015","unstructured":"M\u00fcller CA, Geisel O, Pelz P, Higl V, Kr\u00fcger J, Stickel A, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2015;25(8):1167\u201377.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"416_CR133","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jhep.2008.09.008","volume":"49","author":"P Gache","year":"2008","unstructured":"Gache P, Hadengue A. Baclofen improves abstinence in alcoholic cirrhosis: still better to come? J Hepatol. 2008;49(6):1083\u20135.","journal-title":"J Hepatol"},{"issue":"4","key":"416_CR134","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.addbeh.2011.12.010","volume":"37","author":"L Leggio","year":"2012","unstructured":"Leggio L, Ferrulli A, Zambon A, Caputo F, Kenna G, Swift R, et al. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav. 2012;37(4):561\u20134.","journal-title":"Addict Behav"},{"issue":"12","key":"416_CR135","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1177\/0091270010385936","volume":"51","author":"S Saddichha","year":"2011","unstructured":"Saddichha S, Jayaram N, Manjunatha N, Benegal V. Baclofen-induced morbiliform rashes: a case series. J Clin Pharmacol. 2011;51(12):1733\u20134.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"416_CR136","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0376-8716(93)90057-W","volume":"33","author":"E Krupitsky","year":"1993","unstructured":"Krupitsky E, Burakov A, Ivanov V, Krandashova G, Lapin I, Grinenko AJ, et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug Alcohol Depend. 1993;33(2):157\u201363.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"416_CR137","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","volume":"34","author":"JC Garbutt","year":"2010","unstructured":"Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34(11):1849\u201357.","journal-title":"Alcohol Clin Exp Res"},{"issue":"6","key":"416_CR138","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/alcalc\/agu062","volume":"49","author":"K Morley","year":"2014","unstructured":"Morley K, Baillie A, Leung S, Addolorato G, Leggio L, Haber P. Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol. 2014;49(6):654\u201360.","journal-title":"Alcohol Alcohol"},{"key":"416_CR139","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jsat.2014.11.007","volume":"52","author":"AM Ponizovsky","year":"2015","unstructured":"Ponizovsky AM, Rosca P, Aronovich E, Weizman A, Grinshpoon A. Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1\u00a0year follow-up. J Subst Abuse Treat. 2015;52:24\u201330.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"416_CR140","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/alcalc\/agr017","volume":"46","author":"G Addolorato","year":"2011","unstructured":"Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, et al. Dose\u2013response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2011;46(3):312\u20137.","journal-title":"Alcohol Alcohol"},{"key":"416_CR141","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fpsyt.2012.00103","volume":"3","author":"R Beaurepaire De","year":"2012","unstructured":"De Beaurepaire R. Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients. Front Psychiatry. 2012;3:3\u20137.","journal-title":"Front Psychiatry"},{"issue":"10","key":"416_CR142","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.euroneuro.2015.05.008","volume":"25","author":"B Rolland","year":"2015","unstructured":"Rolland B, Labreuche J, Duhamel A, Deheul S, Gautier S, Auffret M, et al. Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol. 2015;25(10):1631\u20136.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"416_CR143","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/JCP.0000000000000054","volume":"34","author":"B Rolland","year":"2014","unstructured":"Rolland B, Jaillette E, Carton L, Bence C, Deheul S, Saulnier F, et al. Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder. J Clin Psychopharmacol. 2014;34(1):153\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"416_CR144","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/YIC.0000000000000054","volume":"30","author":"B Rolland","year":"2015","unstructured":"Rolland B, Valin T, Langlois C, Auffret M, Gautier S, Deheul S, et al. Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study. Int Clin Psychopharmacol. 2015;30(1):49\u201353.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"416_CR145","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/alcalc\/agt169","volume":"49","author":"N Franchitto","year":"2014","unstructured":"Franchitto N, Pelissier F, Lauque D, Simon N, Lan\u00e7on C. Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series. Alcohol Alcohol. 2014;49(1):79\u201383.","journal-title":"Alcohol Alcohol"},{"issue":"1","key":"416_CR146","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1742-6723.2006.00805.x","volume":"18","author":"NY Leung","year":"2006","unstructured":"Leung NY, Whyte IM, Isbister GK. Baclofen overdose: defining the spectrum of toxicity. Emerg Med Australas. 2006;18(1):77\u201382.","journal-title":"Emerg Med Australas."},{"issue":"4","key":"416_CR147","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bcpt.12161","volume":"114","author":"P Pommier","year":"2014","unstructured":"Pommier P, Debaty G, Bartoli M, Viglino D, Carpentier F, Danel V, et al. Severity of deliberate acute baclofen poisoning: a nonconcurrent cohort study. Basic Clin Pharmacol Toxicol. 2014;114(4):360\u20134.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"416_CR148","volume-title":"Australian guidelines to reduce health risks from drinking alcohol","author":"National Health Medical Research Council","year":"2009","unstructured":"National Health Medical Research Council. Australian guidelines to reduce health risks from drinking alcohol. Canberra: Commonwealth of Australia; 2009."},{"issue":"3","key":"416_CR149","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","volume":"26","author":"JJ Suh","year":"2006","unstructured":"Suh JJ, Pettinati HM, Kampman KM, O\u2019Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006;26(3):290\u2013302.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"416_CR150","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1001\/archinte.168.11.1188","volume":"168","author":"BA Johnson","year":"2008","unstructured":"Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Int Med. 2008;168(11):1188\u201399.","journal-title":"Arch Int Med."},{"issue":"14","key":"416_CR151","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","volume":"298","author":"BA Johnson","year":"2007","unstructured":"Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641\u201351.","journal-title":"JAMA"},{"issue":"18","key":"416_CR152","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889\u2013900.","journal-title":"JAMA"},{"issue":"10","key":"416_CR153","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.4088\/JCP.11r07485","volume":"73","author":"N Iovieno","year":"2012","unstructured":"Iovieno N, Papakostas GI. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. J Clin Psychiatry. 2012;73(10):1300\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"416_CR154","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40800-014-0001-1","volume":"1","author":"N Joshi","year":"2014","unstructured":"Joshi N, McMillan S. Drug safety: case reports. Drug Saf Case Rep. 2014;1(1):1\u20132.","journal-title":"Drug Saf Case Rep."},{"issue":"2","key":"416_CR155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1192\/bjp.bp.111.096594","volume":"200","author":"S Leucht","year":"2012","unstructured":"Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry. 2012;200(2):97\u2013106.","journal-title":"Br J Psychiatry"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-016-0416-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-016-0416-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-016-0416-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T10:04:23Z","timestamp":1718445863000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-016-0416-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,29]]},"references-count":155,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1007\/s40264-016-0416-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,29]]}}}